324 related articles for article (PubMed ID: 36905579)
1. Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
[TBL] [Abstract][Full Text] [Related]
2. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
3. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
4. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
[TBL] [Abstract][Full Text] [Related]
5. Emerging Targeted and Immune-Based Therapies in Sarcoma.
Pollack SM; Ingham M; Spraker MB; Schwartz GK
J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
[TBL] [Abstract][Full Text] [Related]
6. New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.
Seong G; D'Angelo SP
Front Oncol; 2023; 13():1150765. PubMed ID: 37007160
[TBL] [Abstract][Full Text] [Related]
7. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
[TBL] [Abstract][Full Text] [Related]
8. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
Banks LB; D'Angelo SP
J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Sarcoma: Where Do Things Stand?
Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
[TBL] [Abstract][Full Text] [Related]
12. Role of Immunotherapy in Sarcomas.
Dalal S; Shan KS; Thaw Dar NN; Hussein A; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279265
[TBL] [Abstract][Full Text] [Related]
13. Next frontiers in systemic therapy for soft tissue sarcoma.
Yen CC; Chen TW
Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor.
Baldi GG; Gronchi A; Tazzari M; Stacchiotti S
Expert Rev Anticancer Ther; 2022 May; 22(5):491-503. PubMed ID: 35412415
[TBL] [Abstract][Full Text] [Related]
15. Potential for immunotherapy in soft tissue sarcoma.
Tseng WW; Somaiah N; Engleman EG
Hum Vaccin Immunother; 2014; 10(11):3117-24. PubMed ID: 25625925
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond.
Fazel M; Dufresne A; Vanacker H; Waissi W; Blay JY; Brahmi M
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980528
[TBL] [Abstract][Full Text] [Related]
17. Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
Ozaniak A; Vachtenheim J; Lischke R; Bartunkova J; Strizova Z
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440139
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
19. Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.
Jeong S; Afroz S; Kang D; Noh J; Suh J; Kim JH; You HJ; Kang HG; Kim YJ; Kim JH
Mol Cells; 2023 Oct; 46(10):579-588. PubMed ID: 37853684
[TBL] [Abstract][Full Text] [Related]
20. Correlative Study on the Relationship between the Expression of m6a-Related Genes and the Prognosis and Immunotherapy of Soft Tissue Sarcoma.
Qiu Y; Li J; Yao J; Meng J; Huang X; Zheng X; Wen Z; Huang J; Wang H
Biomed Res Int; 2022; 2022():5439023. PubMed ID: 38024481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]